Aptevo Therapeutics (APVO) Stock Price, News & Analysis

Company Overview

Aptevo Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in Seattle, Washington, focused on the discovery and development of novel immunotherapies for oncology and autoimmune diseases. Founded in 2012 as a spin-off from Emergent BioSolutions, the company builds on expertise in protein engineering and translational research to create targeted biologics that engage the body’s immune system.

The company’s core technologies include the ADAPTIR platform, which enables the design of bispecific and multispecific protein scaffolds with customizable binding domains, and the KNOCKOUT platform, which incorporates non-natural amino acids to enhance therapeutic properties such as stability and half-life. Key product candidates in Aptevo’s pipeline include AFM13, a CD30/CD16A innate cell engager in development for CD30-positive lymphomas, and APVO436, a bispecific molecule targeting CD123 and CD3 for acute myeloid leukemia.

Aptevo Therapeutics conducts clinical studies across North America and Europe, partnering with academic centers and industry collaborators to advance its lead candidates through Phase 1/2 trials. The company’s approach emphasizes dual activation of innate and adaptive immune responses to achieve potent antitumor effects while reducing the risk of off-target toxicity.

Guided by a management team with extensive experience in biologic drug development and cell-based therapies, Aptevo continues to expand its pipeline and seek strategic partnerships to bring its immunotherapeutic candidates to patients with high-unmet medical needs.

Key Stats

• Today's Range: $2.31 to $2.46
• 50-Day Range: $2.37 to $4.76
• 52-Week Range: $2.30 to $48.78
• Volume: 21,523 shs
• Average Volume: 49,177 shs
• Market Capitalization: $4.29 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Hold

Aptevo Therapeutics Stock Analysis - MarketRank™

Aptevo Therapeutics scored higher than 29% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.4 / 5
• Analyst Rating: Hold

Consensus Rating

Aptevo Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 strong buy rating, no buy ratings, 1 hold rating, and 1 sell rating.

Amount of Analyst Coverage

Aptevo Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Aptevo Therapeutics are expected to grow in the coming year, from ($19.30) to ($6.59) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Aptevo Therapeutics is -0.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Aptevo Therapeutics is -0.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Aptevo Therapeutics has a P/B Ratio of 0.71. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.56% of the float of Aptevo Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Aptevo Therapeutics has a short interest ratio ("days to cover") of 2.42, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Aptevo Therapeutics has recently decreased by 6.71%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Aptevo Therapeutics does not currently pay a dividend.

Dividend Growth

Aptevo Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 1.8 / 5
• News Sentiment: 0.93

News Sentiment

Aptevo Therapeutics has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Aptevo Therapeutics this week, compared to 2 articles on an average week.

Company Ownership

• Score: 0.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Aptevo Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

0.48% of the stock of Aptevo Therapeutics is held by insiders.

Percentage Held by Institutions

8.06% of the stock of Aptevo Therapeutics is held by institutions.

Company Calendar

• Last Earnings: 8/14/2026
• Today: 8/30/2026
• Next Earnings (Estimated): 11/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:APVO
• CIK: 1671584
• Web: www.aptevotherapeutics.com
• Phone: (206) 838-0500
• Fax: 206-838-0503
• Employees: 50
• Year Founded: 2016

Profitability

• EPS (Trailing Twelve Months): ($51.83)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$25.97 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -201.49%
• Return on Assets: -119.21%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.08
• Quick Ratio: 2.08

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.34 per share
• Price / Book: 0.71

Miscellaneous

• Outstanding Shares: 1,810,000
• Free Float: 1,801,000
• Market Cap: $4.29 million
• Optionable: Not Optionable
• Beta: 1.65